TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04952584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD30.CAR-EBVST cells
Description: The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
Study: NCT04728334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
Study: NCT05463445

Intervention type: OTHER
Intervention: Only observation
Description: No intervention is needed.

Intervention type: OTHER
Intervention: Only observation
Description: No intervention is needed.
Study: NCT05577663

Intervention type: OTHER
Group type: OTHER
Intervention: Routine treatment of the extraction socket
Description: Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket seal technique by a free gingival graft
Description: Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket seal technique using a synthetic resorbable membrane
Description: Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
Study: NCT05959421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERVEBO® (rVSV∆G-ZEBOV-GP)
Description: intramuscular vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERVEBO® (rVSV∆G-ZEBOV-GP)
Description: intramuscular vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERVEBO® (rVSV∆G-ZEBOV-GP)
Description: intramuscular vaccination
Study: NCT03996044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teeth brushing and flossing
Description: All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teeth brushing and flossing
Description: All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teeth brushing and flossing
Description: All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teeth brushing and flossing
Description: All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Description: Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
Study: NCT05335577

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Claudin-2
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Claudin-2
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Claudin-2
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Caveolin-1
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Caveolin-1
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Caveolin-1
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary EGF
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary EGF
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
Study: NCT03996044

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy (aPDT)
Description: One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
Study: NCT05335577

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary EGF
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
Study: NCT03996044

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy (aPDT)
Description: One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
Study: NCT04902820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEPTECH website
Description: The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online PrEP resource list
Description: Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
Study: NCT05023304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study: NCT06109090

Intervention type: OTHER
Intervention: Neuropsychological testing
Description: In this study, the Vineland Adaptive Behavior Scale is administered, which evaluates the child's adaptive functioning, particularly in four areas: communication, socialization, daily living skills, and motor activities. The Child Behavior Checklist (CBCL) questionnaire is also administered, which is a questionnaire given to parents that highlights elements related to internalizing and externalizing behavioral disorders.~For the assessment of executive functions, a series of tests are administered to evaluate specific functions. These tests are chosen from a list of available tests according to the document from the Italian Society of Child Neuropsychiatry, titled Assessment of attention and executive functions in developmental age: review of Italian instruments and proposal of a battery for in-depth analysis.
Study: NCT06422702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosomatic Symptoms Intervention
Description: Psychosomatic symptoms included intervention of negative psychological symptoms and intervention of physical discomfort symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Extended supportive care
Description: The control group implemented continuity of supportive care based on primary care
Study: NCT05903716

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormone
Description: At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormone
Description: At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients

Intervention type: DRUG
Intervention: Isotretinoin
Description: İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
Study: NCT05072184

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESP block
Description: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
Study: NCT05238064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
Study: NCT06279572

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT04568954

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Truenat TB platform/TB assays
Description: Truenat TB platform/TB assays, a molecular diagnostic test developed by Molbio diagnostics, for the diagnosis of Mycobacterium tuberculosis complex (MTBC) and Truenat MTB-RIF Dx for detection of RIF resistance was endorsed in 2020 by the WHO for TB diagnosis.~The system has been designed to be operated as a point-of-care- diagnostic solution in peripheral laboratories with minimal infrastructure.~It takes about 25 minutes to do the DNA extraction and another 35 minutes to diagnose TB.~It is portable and battery operated, have no need for a computer or laptop, and operate from 2-40 C ambient temperature. The system uses room temperature stable reagents with long shelf life.
Study: NCT06539507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX17725
Description: BCX17725 for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX17725
Description: BCX17725 for injection
Study: NCT04770246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed orally every day on a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed intermittently on a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed orally every day or intermittently on a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
Study: NCT05634083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Uremic pateints with itching
Description: Activated charcoal
Study: NCT06287827

Intervention type: PROCEDURE
Intervention: Simplified protocol
Description: MUAC-based dosing:~* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets Ready to use Therapeutic Food (RUTF)/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day).

Intervention type: PROCEDURE
Intervention: Standard protocol
Description: Weight-based dosing~* SAM: Mid-upper-arm circumference (MUAC) \<115mm or Weight-Height/length Z Score \<-3 or mild or moderate bipedal oedema: 150-185 kcal/kg/day is offered using RUTF until the patient passes to MAM and then the dose is reduced to 100 -130 kcal/kg/day using RUTF until recovery.~* MAM: MUAC 115-\<125mm or Weight-Height/length Z Score \<-2: 100-130 kcal/kg/day is offered using RUTF until recovery.
Study: NCT05310786

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
Description: This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
Description: This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
Study: NCT05405361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Intravenous administration of ARGX-117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Intravenous administration of ARGX-117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration of placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration of placebo
Study: NCT06497972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White bread (control)
Description: Matched to the carbohydrate content of the wild rice blend rice cake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice cake
Description: A 40g rice cake made of 100% brown rice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wild rice (25%) and brown rice (75%) cake
Description: A 40g rice cake made of a blend of 25% wild rice and 75% brown rice
Study: NCT05859009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Guided Therapy of Glue and Coil
Description: This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Guided Therapy of Glue and Coil
Description: This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Selective Beta Blockers (Propanolol)
Description: Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Selective Beta Blockers (Propanolol)
Description: Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
Study: NCT05958147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-PRF
Description: thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
Study: NCT06127524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEM Scanner
Description: Implementation of the SEM Scanner as part of weekly standard skin assessments of sacrum and heels
Study: NCT06147063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD9838
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD9838
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed mRNA vaccine
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed mRNA vaccine
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD6563
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD6563
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD6563
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD6563
Description: Intramuscular (IM) injection.